Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02459626
Other study ID # 1.02
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 2014
Est. completion date December 2018

Study information

Verified date May 2021
Source Heart Center Leipzig - University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

StiffMAP-HFpEF trial is an investigator initiated, observational, single-center study that will evaluate whether fibrosis quantification by cardiac MRI correlates with left and right ventricular stiffness derived from pressure-volume analysis, aiming to clarify if cardiac MRI is a valid, non-invasive method to assess diastolic function in patients with Heart Failure with preserved ejection fraction.


Description:

Heart Failure with preserved ejection fraction (HFpEF) and diastolic dysfunction is a growing medical challenge. To date almost every second patient with heart failure has a preserved ejection fraction and recent data show that outcomes in these patients are as bad as in those with reduced ejection fraction. In clinical routine the diagnosis of HFpEF is complicated by indirect assessment of diastolic function. Mechanistically the diastolic dysfunction is among others believed to be caused by the development of diffuse myocardial fibrosis with an increase of extracellular matrix. Direct assessment of the intrinsic diastolic function and stiffness of the ventricle can be obtained by pressure-volume-curve tracings through a conductance catheter. Although this offers the benefit of assessing load-dependent and load-independent parameters of diastolic function as well as information on contractility and ventricular-arterial coupling, the use of this technique is limited by its invasiveness in daily care. Newer MRI techniques have made it possible to quantify not only local fibrosis but also diffuse fibrosis (i.e. T1-Mapping) and determine extracellular volumes. Moreover, the role of right ventricular function is in HFpEF is not well defined. Aim of the current study is therefore to evaluate the role of MRI in assessing cardiac fibrosis in the context of impaired LV diastolic function in HFpEF patients, as well as to evaluate the role of systolic and diastolic right ventricular functional impairment in this patient cohort.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date December 2018
Est. primary completion date May 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - LV-EF > 50% - Indication for invasive cardiac catheterization Exclusion Criteria: - know CAD or CAD in Angiography (stenoses > 50%) - acute coronary syndromes - Cerebral ischemia within the last year - contraindications for MRI - more than mild valvular disease - Constrictive pericarditis, restrictive Cardiomyopathy, pericardial effusion - pregnancy - enrolment in other study

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Diagnostic P-V-loops and MRI
Invasive assessment of P-V-loops during catheterization for suspected CAD Magnetic resonance Imaging for assessment of myocardial fibrosis and biventricular function

Locations

Country Name City State
Germany Heart Center of the University Leipzig Leipzig

Sponsors (1)

Lead Sponsor Collaborator
Heart Center Leipzig - University Hospital

Country where clinical trial is conducted

Germany, 

References & Publications (5)

Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006 Jul 20;355(3):260-9. — View Citation

Burkhoff D, van der Velde E, Kass D, Baan J, Maughan WL, Sagawa K. Accuracy of volume measurement by conductance catheter in isolated, ejecting canine hearts. Circulation. 1985 Aug;72(2):440-7. — View Citation

Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006 Jul 20;355(3):251-9. — View Citation

Sibley CT, Noureldin RA, Gai N, Nacif MS, Liu S, Turkbey EB, Mudd JO, van der Geest RJ, Lima JA, Halushka MK, Bluemke DA. T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy. Radiology. 2012 Dec;265(3):724-32. doi: 10.1148/radiol.12112721. Epub 2012 Oct 22. — View Citation

Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, Weitmann K, Hoffmann W, Poller W, Pauschinger M, Schultheiss HP, Tschöpe C. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation. 2008 Apr 22;117(16):2051-60. doi: 10.1161/CIRCULATIONAHA.107.716886. Epub 2008 Apr 14. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Correlation of extracellular volume (MRI) and myocardial stiffness (p-v-loops) Baseline
Secondary LV stiffness constant (ß) between groups Baseline
Secondary Time constant of LV-relaxation (?) between groups Baseline
Secondary Change in endiastolic pressure volume relation (EDPVR) under excercise between groups Baseline
Secondary Right Ventricular Endsystolic Elastance Slope Baseline
Secondary Right Ventricular Endsystolic Stiffness Constant Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Completed NCT02173548 - Interleukin-1 Blockade in HF With Preserved EF Phase 2
Completed NCT03310099 - Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness, Metabolic Flexibility and Glucose Tolerance in Obese Patients N/A
Completed NCT02638961 - Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of HFpEF N/A
Completed NCT03871803 - β-blockers Withdrawal in Patients With HFpEF and Chronotropic Incompetence: Effect on Functional Capacity (Preserve-HR) Phase 4
Completed NCT03672591 - Renal Hemodynamics in Patients With HFpEF
Recruiting NCT03620526 - Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction Phase 4
Active, not recruiting NCT03624010 - Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients Phase 2
Completed NCT03541603 - Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF Phase 2
Completed NCT03141567 - LYmphangiogenesis FacTors in Heart Failure States
Completed NCT02744339 - Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction Phase 2
Completed NCT03387813 - Hemodynamic-GUIDEd Management of Heart Failure N/A
Completed NCT03186833 - The Heart Failure With Preserved Ejection Fraction (HFpEF) Pathophysiology Study.
Completed NCT03289481 - Treatment of HFpEF With Nitrate Supplement Early Phase 1
Terminated NCT03195660 - Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study N/A
Completed NCT03226652 - Heart Function in Patients Assessed for Sleep Apnoea
Completed NCT03966755 - Unsaturated Fatty Acids to Improve Cardiorespiratory Fitness in Obesity and HFpEF N/A
Not yet recruiting NCT04282850 - Ablation Versus Medical Management of Atrial Fibrillation in HFpEF N/A
Recruiting NCT03184311 - High-intensity Interval Training in Heart Failure Patients With Preserved Ejection Fraction N/A
Withdrawn NCT03317314 - Cardiopulmonary Interactions in Patients With Heart Failure